sa���ʴ�ý������ҳ���

• Reflects Catalent’s unparalleled service and best-in-class capabilities across the pharmaceutical, biotech and consumer health categories
• Reinforces Catalent’s position as a trusted partner in achieving Patient First outcomes

October 28, 2025 — TAMPA, Fla. – sa���ʴ�ý������ҳ���., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company’s commitment to delivering unparalleled customer service and its focus on “championing the missions that matter.” The new approach reflects Catalent’s dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solutions to those who need them most.

“At Catalent, we believe that every medicine, therapy and product we help develop, manufacture and deliver exemplifies our commitment to put patients first in everything we do,” said Alessandro Maselli, President and Chief Executive Officer. “This new brand and simplified approach speak not only to who we are today, but to the impact we have on global health, working side-by-side with our customers to achieve their goals and transform lives around the world.”

Catalent’s new brand comes at a pivotal time, as the company continues to build momentum and expand its global impact following its transition to private ownership under Novo Holdings in December of 2024. With the recent announcement of its new global headquarters in Tampa, Fla., sa���ʴ�ý������ҳ���anchors its operations across more than 40 sites worldwide, reinforcing Catalent’s global reach and readiness to meet the demands of an increasingly complex global healthcare ecosystem.

“Our customers count on us to help drive their efforts to make a difference in people’s lives,” said Trish Hunt, Group Vice President and Chief Marketing Officer. “Our new branding reflects exactly who we are and how we deliver: a company that puts patients first, provides tailored solutions with unparalleled service and champions every customer’s mission as if it were our own. It’s a bold step forward that aligns our identity with the experience that sets sa���ʴ�ý������ҳ���apart.”

Over the past decade, sa���ʴ�ý������ҳ���has supported the development and manufacture of products representing half of all FDA approvals. The company produces over 60 billion doses per year and has over 1,000 active development programs at any given time. This scale and expertise enables sa���ʴ�ý������ҳ���to meet the unique and evolving needs of the healthcare industry. sa���ʴ�ý������ҳ���has deep partnerships with customers of all sizes, from small or virtual organizations to large global companies. The company scales its approach according to what its customers need for their program to be a success.

The new branding is being launched today at CPHI Frankfurt and SupplySide Global, as well as on Catalent’s website () and social media channels and through updated marketing materials. The company’s global sites will transition to the new branding and structure over the coming months while maintaining uninterrupted service to customers.

ABOUT CATALENT

sa���ʴ�ý������ҳ���. is a leading global contract development and manufacturing organization (CDMO) championing missions that help people live better and healthier lives. Every product that sa���ʴ�ý������ҳ���helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. sa���ʴ�ý������ҳ���provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. sa���ʴ�ý������ҳ���tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, sa���ʴ�ý������ҳ���supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit .

CONTACTS

Media:
[email protected]